T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.51 NOK 1.21%
Market Cap: 617.1m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

P/E
Price to Earnings

-14.8
Current
-2.7
Median
21.3
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-14.8
=
Market Cap
584.8m NOK
/
Net Income
-39.6m NOK
All Countries
Close
Market Cap P/E
NO
Thor Medical ASA
OSE:TRMED
584.8m NOK -14.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -182 852.2
US
Abbvie Inc
NYSE:ABBV
315.4B USD 62.1
US
Amgen Inc
NASDAQ:AMGN
142B USD 33.6
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 881.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD -221.4
US
Epizyme Inc
F:EPE
94.1B EUR -467.3
AU
CSL Ltd
ASX:CSL
139B AUD 32.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 17.4
US
Seagen Inc
F:SGT
39.3B EUR -54.1
NL
argenx SE
XBRU:ARGX
38.2B EUR -348.7
Earnings Growth PEG
NO
T
Thor Medical ASA
OSE:TRMED
Average P/E: 205.4
Negative Multiple: -14.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -182 852.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
881.5
21%
42
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -221.4
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -467.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.7
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -348.7 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-4.7
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A